Loss of expression of SMARCB1 has been reported in colorectal adenocarcinomas and has been associated with higher histological grade, larger tumor size, poor overall survival, MSI, and the BRAF V600E mutation (Wang et al, 2016). This evidence concerns the gene SMARCB1 and neoplasm.